Abeona Therapeutics Inc (ABEO) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Abeona Therapeutics Inc in the second quarter 2026?
Abeona Therapeutics Inc recorded a cumulative net loss of $-63 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -41.69%.
Within the Major Pharmaceutical Preparations industry 144 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 244, from total ROE ranking in the first quarter 2026 at 254.
In the fast-evolving sphere of biopharmaceuticals, maintaining a competitive edge is crucial, especially for companies like Abeona Therapeutics Inc. (Nasdaq: ABEO), which is devoted to developing groundbreaking gene therapies aimed at treating rare genetic disorders. Recently, the company announced a strategic move in the form of equity awards granted to new non-executive employees, reflecting its commitment to attracting and retaining talent even amidst financial challenges. A Strategic Approach to Employee Inducements On December 2, 2024, Abeona Therapeutics disclosed that it had granted equity awards to newly onboarded employees, a decision that underscores its adherence to Nasdaq Listing Rule 5635(c)(4). This regulation permits companies to offer inducement grants to prospective employees as a way of fostering commitment and enthusiasm in their workforce. This recent round of employee inducements follows an earlier announcement on November 1, revealing the company’s ongoing efforts to stabilize its workforce and fuel its ambitious corporate objectives. With the biopharmaceutical sector grappling with economic headwinds, attracting top-notch talent is a strategic imperative for Abeona.
Abeona Therapeutics Faces Financial Headwinds While Pursuing Gene Therapy Approval: A Close Look at Recent Developments and Employee InducementsAbeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company focused on developing innovative gene therapies, has recently announced the granting of equity awards to new non-executive employees as part of their efforts to revolutionize treatment for rare genetic disorders. This decision was made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company s ongoing commitment to attracting and retaining talent despite its challenging financial landscape. Recent Employee Inducement GrantsOn November 1, 2024, Abeona Therapeutics reported that it has awarded equity grants to non-executive employees who have recently joined the organization. These inducements not only serve to enhance employee morale but also aim to incentivize high performance and loyalty in a high-stakes environment. By offering an equity stake, Abeona positions itself as a competitive and attractive workplace, particularly amidst the turmoil faced within the biopharmaceutical industry.
Abeona Therapeutics: Navigating Financial Turbulence in the Quest for Gene Therapy ApprovalCLEVELAND — In the high-stakes world of biotech, few situations are as precarious as the race for the next groundbreaking treatment. Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company, finds itself at this critical juncture, recently resubmitting its Biologics License Application (BLA) for its investigational gene therapy, prademagene zamikeracel (pz-cel), to the U.S. Food and Drug Administration (FDA). The therapy aims to treat patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder, but it comes against a backdrop of significant financial challenges.For the 12 months ending in the first quarter of 2024, Abeona reported a staggering cumulative net loss of $77 million, leading to a catastrophic return on equity (ROE) of -821.46%. Such figures not only reflect the financial strain under which the company operates but also raise questions about its long-term viability and ability to bring pz-cel to market.
Abeona Therapeutics Secures $50 Million Credit Facility to Accelerate Growth CLEVELAND, Jan. 08, 2024 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading biopharmaceutical company focused on developing transformative gene and cell therapies, announced today a major milestone in its financial strategy. The company has successfully secured a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. This new credit agreement, with a term of three and a half years, will provide Abeona Therapeutics with the necessary capital to fuel its ongoing research and development efforts. Under the terms of the credit facility, the funding will be available in multiple tranches. The first tranche of $20 million will be released upon closing, followed by a committed capital of $10 million in a second tranche. Additionally, Abeona has an option to further increase the credit facility by an additional $20 million, provided certain terms and conditions are met. This infusion of capital will allow Abeona Therapeutics to strengthen its financial position, enabling it to drive innovation and growth in the highly competitive pharmaceutical industry.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
